

# National Agency for Food & Drug Administration & Control (NAFDAC)

**Registration & Regulatory Affairs (R & R) Directorate**

**SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) TEMPLATE**

### NAME OF THE MEDICINAL PRODUCT

KALCEP-100 mg dry syrup

### QUALITATIVE AND QUANTITATIVECOMPOSITION

Each 5ml of Reconstituted suspension contains:

Cefpodoxime Proxetil USP

Equivalent to Cefpodoxime: 100 mg

For a full list of excipients, see section 6.1

## **PHARMACEUTICAL FORM**

## White to yellowish white flavoured granular powder which on addition of water gives orange coloured flavoured suspension.

### Clinical particulars

* 1. **Therapeutic indications**

KALCEP-100 DRY SYRUP are indicated for the treatment of:

• Upper respiratory tract infections

- Acute bacterial sinusitis

- Tonsillitis

• Lower respiratory tract infections

- Bacterial pneumonia

- Cefpodoxime might not be suitable option depending on the pathogen involved. Consideration should be given to the official guidance on the appropriate use of antibacterial agents.

### Posology and method of administration

DOSAGE AND DIRECTIONS FOR USE

The dosage depends on the weight of the child being treated. The average dose is 8 mg/kg/day administered in two doses at 12 hourly intervals. It must be taken with meals since an increase in gastric pH results in decreased bioavailability.

The following table may be used as a dosage guide:

Weight (kg) per Dose

Between 10 and 15 kg: 5 mL every 12 hours

>15 kg: 10 mL every 12 hours

The use of KALCEP-50 DRY SYRUP in children under one year of age is currently not indicated since insufficient clinical data is available at present.

Elderly patients: Where renal function is normal, it is not necessary to adjust the dose.

Renal insufficiency in adults and children:

When the creatinine clearance is above 40 mL/min, it is not necessary to adjust the dose.

For values below 40 mL/min, the daily dosage regimen should be reduced by half and administered as a single daily dose for values 10 - 39 mL/min, every second day for values below 10 mL/min and after each dialysis session for haemodialysis patients.

**Method of administration:** Oral

### Contraindications

KALCEP-100 DRY SYRUP is contra-indicated in:

• Hypersensitivity to cefpodoxime, any other cephalosporins or to any of the excipients.

• Previous history of immediate and or severe hypersensitivity reaction (anaphylaxis) to penicillin or other betalactam antibiotic.

### Special warnings and precautions for use

* Cefpodoxime is not a preferred antibiotic for the treatment of staphylococcal pneumonia and should not be used in the treatment of atypical pneumonia caused by organisms such as Legionella, Mycoplasma and Chlamydia. Cefpodoxime is not recommended for the treatment of pneumonia due to S. pneumonia.
* As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefpodoxime must be discontinued immediately and adequate emergency measures must be initiated.
* Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefpodoxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefpodoxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.
* In cases of severe renal insufficiency it may be necessary to reduce the dosage regimen dependent on the creatinine Clearance.
* Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all antibacterial agents, including cefpodoxime, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of cefpodoxime. Discontinuation of therapy with cefpodoxime and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.
* Cefpodoxime should always be prescribed with caution in patients with a history of gastrointestinal disease, particularly colitis.
* As with all beta-lactam antibiotics, neutropenia and more rarely agranulocytosis may develop particularly during extended treatment. For cases of treatment lasting longer than 10 days, the blood count should be monitored and treatment discontinued if neutropenia is found.
  1. **Interaction with other medicinal products and other forms of interaction**
* No clinically significant drug interactions have been reported during the course of clinical studies.
* Histamine H -antagonists and antacids reduce the bioavailability of cefpodoxime. Probenecid reduces the excretion of cephalosporins. Cephalosporins potentially enhance the anticoagulant effect of coumarins and reduce the contraceptive effect of oestrogens.
* Oral anticoagulants: Simultaneous administration of cefpodoxime with warfarin may augment its anti-coagulant effects. There have been many reports of increases in oral anti-coagulant activity in patients receiving antibacterial agents, including cephalosporins. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the cephalosporins to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after coadministration of cefpodoxime with an oral anti-coagulant agent. Studies have shown that bioavailability is decreased by approximately 30% when cefpodoxime is administered with drugs which neutralise gastric pH or inhibit acid secretions. Therefore, such drugs as antacids of the mineral type and H blockers such as ranitidine, which can cause an increase in gastric pH, should be taken 2 to 3 hours after Cefpodoxime administration.

### Pregnancy and Lactation

**Pregnancy:**

There are no or limited amount of data from the use of cefpodoxime in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Due to the benefit of antibiotic treatment, the use of cefpodoxime may be considered during pregnancy if necessary. Caution should be exercised when prescribing to pregnant women.

**Lactation:**

Cefpodoxime is excreted in breast milk in small amounts. Cefpodoxime may be used during breast-feeding. Continuation of breast-feeding should be questioned in case of diarrhoea or mucosal fungus infection in the Breast fed infant. The possibility of sensitisation should be borne in mind.

**Fertility:** No data available

### Effects on ability to drive and use machines

Attention should be drawn to the risk of dizzy sensations.

### Undesirable effects

Adverse drug reactions are listed below by system organ class and frequency. Frequencies are defined as:

Very common (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1/1,000 to <1/100)

Rare (≥1/10,000 to <1/1,000)

Very rare (<1/10,000), not known (cannot be estimated from the available data)

**Blood and lymphatic system disorders**

Rare: Haematological disorders such as reduction in haemoglobin, thrombocytosis, thrombocytopenia,

leucopenia and eosinophilia.

Very rare: Haemolytic anaemia.

**Nervous system disorders**

Uncommon: Headache, paraesthesia, dizziness

**Ear and labyrinth disorders**

Uncommon: Tinnitus

**Gastrointestinal disorders**

Common: Gastric pressure, nausea, vomiting, abdominal pain, flatulence, diarrhoea.

Bloody diarrhoea can occur as a symptom of enterocolitis.

The possibility of pseudomembranous enterocolitis should be considered if severe or persistent diarrhoea occurs during or after treatment.

**Metabolism and nutrition disorders**

Common: Loss of appetite

**Immune system disorders**

Hypersensitivity reactions of all degrees of severity have been observed.

Very rare: anaphylactic reactions, bronchospasm, purpura and angioedema.

**Renal and urinary disorders**

Very rare: Slight increases in blood urea and creatinine

**Hepato-biliary disorders**

Rare: Transient moderate elevations of ASAT, ALAT and alkaline phosphatase and/or bilirubin. These

laboratory abnormalities which may be explained by the infection,

may rarely exceed twice the upper limit of the named range and elicit a pattern of liver injury, usually

cholestatic and most often asymptomatic.

Very rare: liver damage

**Skin and subcutaneous tissue disorders**

Uncommon: Hypersensitivity mucocutaneous reactions, rash, urticaria, pruritus

Very rare: Stevens- Johnson syndrome, toxic epidermal necrolysis and erythema multiforme

**Infections and infestations**

There can be multiplication of non-sensitive micro-organisms (see section 4.4)

### Overdose

In the event of overdosage with cefpodoxime, supportive and symptomatic therapy is indicated.

In cases of overdosage, particularly in patients with renal insufficiency, encephalopathy may occur. The encephalopathy is usually reversible once cefpodoxime plasma levels have fallen.

### PHARMACOLOGICAL PROPERTIES

* 1. **Pharmacodynamics properties**

**Pharmacotherapeutic group:** Beta-lactam antibacterial, a 3rd generation cephalosporin.

**ATC Code:** J01DD13

**Mechanism of Action:**

Cefpodoxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

**PK/PD relationship**

For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with in vivo

efficacy has been shown to be the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of cefpodoxime for individual target species (i.e. %T>MIC).

**Mechanism(s) of resistance:**

Resistance to cephalosporins results from a variety of mechanisms:

1) alteration of the cell-wall permeability of gram-negative bacteria.

2) alteration of the penicillin binding proteins (PBPs)

3) β-lactamase production

4) bacterial efflux pumps

**Break points:**

European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints for MIC testing is presented below. EUCAST clinical MIC breakpoints for cefpodoxime (2011-01-05, v 1.3)

|  |  |  |
| --- | --- | --- |
| Organism | Susceptible (S) (mg/l) | Resistant (R) (mg/l) |
| Enterobacteriaceae  (uncomplicated UTI only) | ≤ 1 | >1 |
| Staphylococcus spp. | Note1 | Note1 |
| Streptococcus groups A, B, C and G | Note2 | Note2 |
| Streptococcus pneumonia | ≤ 0.25 | >0.5 |
| Haemophilus influenza | ≤ 0.25  Note3 | >0.5 |
| Moraxella catarrhalis | ≤ 0.25  Note3 | >0.5 |
| Neisseria gonorrhoeae | IE | IE |
| Non-species related breakpoint | IE | IE |

1. Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility.

2. The beta-lactam susceptibility of beta-haemolytic streptococcus groups A, B, C and G is inferred from the penicillin susceptibility.

3. Strains with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate must be sent to a reference laboratory.

\*Insufficient evidence

### Pharmacokinetic properties

**Absorption and Bioavailability:** Cefpodoxime is taken up in the intestine and is hydrolysed to the active metabolite cefpodoxime. When cefpodoxime proxetil is administered orally to fasting subjects as a tablet corresponding to 100 mg of cefpodoxime, 51.5% is absorbed and absorption is increased by food intake.

**Distribution:** The volume of distribution is 32.3 L and peak levels of cefpodoxime occur 2 to 3 hrs after dosing. The maximum plasma concentration is 1.2 mg/L and 2.5 mg/L after doses of 100 mg and 200 mg respectively. Following administration of 100 mg and 200 mg twice daily over 14.5 days, the plasma pharmacokinetic parameters of cefpodoxime remain unchanged. Serum protein binding of cefpodoxime, 40% principally to albumin. This binding is non saturable in type. Concentrations of cefpodoxime in excess of the minimum inhibitory levels (MIC) for common pathogens can be achieved in lung parenchyma, bronchial mucosa, pleural fluid, tonsils, interstitial fluid and prostate tissue.

**Metabolism & Elimination:** As the majority of cefpodoxime is eliminated in the urine, the concentration is high. (Concentrations in 0-4, 4-8, 8-12 hr fractions after a single dose exceed MIC90 of common urinary pathogens). Good diffusion of cefpodoxime is also seen into renal tissue, with concentrations above MIC90 of the common urinary pathogens, 3-12 hrs after an administration of a single 200 mg dose (1.6-3.1μg/g). Concentrations of cefpodoxime in the medullary and cortical tissues is similar.

**Special Population:** Studies in healthy volunteers show median concentrations of cefpodoxime in the total ejaculate 6-12 hrs following administration of a single 200 mg dose to be above the MIC90 of N. gonorrhoeae.The main route of excretion is renal, 80% is excreted unchanged in the urine, with an elimination half-life of approx 2.4 hours.

### Preclinical safety data

Not applicable.

### PHARMACEUTICAL PARTICULARS

* 1. **List of excipients**

|  |  |
| --- | --- |
| MCCP Granules\* | IHS |
| Sodium Carboxymethyl cellulose | BP |
| Flavour Sweet Orange dry | IHS |
| Colloidal Anhydrous Silica | BP |
| Purified Talc | BP |
| Aspartame | BP |
| Colour Sunset Yellow FCF | IHS |
| Citric Acid (Monohydrate) | BP |
| Flavour Pineapple dry | IHS |

### Incompatibilities

Not applicable

### Shelf life

### 24 months

### Special precautions for storage

Store in a cool & dry place. Protect from light, heat and moisture.

KEEP OUT OF REACH OF CHILDREN

### Nature and contents of container<and special equipment for use, administration or implantation>

100 ML HDPE Bottle.

### Special precautions for disposal <and other handling>

No special requirements.

### APPLICANT/MANUFACTURER



Ahmedabad

Email : [info@sagalabs.com](about:blank)

URL : [www.sagalabs.com](about:blank)